Summary
‘Designer drugs’ are substances intended for recreational use which are derivatives of approved drugs so as to circumvent existing legal restrictions. The term as popularised by the lay press lacks precision. Contrary to the popular belief that ‘designer drugs’ are original creations, the majority of these agents are ‘borrowed’ from legitimate pharmaceutical research. They merely represent the most recent developments in the evolution of mindaltering chemicals.
The most extensively studied class of psychoactive compounds is the phenylethylamines (mescaline analogues). This class includes catecholamines, therapeutic agents and numerous illicit derivatives. Subtle alterations of the phenylethylamine molecule give rise to a spectrum of pharmacological properties ranging from pure sympathomimetic stimulation to primarily psychoactive effects. Although most of these compounds are only of historical interest, amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) continue to be used recreationally. Many deaths have been ascribed to this class of compounds. In overdose the differences between these compounds blur and the clinical presentation is similar to that of amphetamine overdose characterised by tachycardia, hypertension, hyperthermia, diaphoresis, mydriasis, agitation, muscle rigidity, and hyper-reflexia. Death usually results from arrhythmias, hyperthermia or intracerebral haemorrhage. Treatment is aggressive and supportive with careful attention to temperature, blood pressure and seizure control.
Synthetic opioid derivatives, which represent the second major class of ‘designer drugs’, are derivatives of fentanyl (e.g. α-methylfentanyl, 3-methylfentanyl) or pethidine (meperidine) and are extremely potent compounds responsible for numerous overdose deaths. Attempts to synthesise pethidine have resulted in the accidental production of MPTP (1-methyl-4-phenyl- 1,2,3,6- tetrahydropyridine), a compound which is metabolised in the brain by the monoamine oxidase system to a toxic intermediate MPP+ which selectively destroys the sustantia nigra, resulting in the rapid onset of severe Parkinsonian symptoms. Naloxone will antagonise the opiate effects of this drug class, although high doses may be required.
Arylhexylamines constitute the third class of ‘designer drugs’. The predominant member of this class is phencyclidine (PCP), a derivative of the anaesthetic ketamine. This unique class of psychoactive agents exhibits broad and complex pharmacological effects. Overdose may result in extreme agitation, psychosis, sympathomimetic excess, hyperthermia and CNS and respiratory depression. Supportive care, benzodiazepines, haloperidol, and repeated doses of activated charcoal are the mainstay of treatment.
Methaqualone derivatives comprise the fourth class of ‘designer drugs’. Although commonly abused, especially in regional waves of popularity and availability, these primarily sedative agents rarely result in intoxication more serious than general central nervous system (CNS) depression.
The toxicology laboratory has a limited role in the evaluation of intoxication resulting from designer drugs. Most laboratories do not have the capability to rapidly and accurately assay for these synthetic analogues, nor are there sufficient data to aid in the interpretation of measured drug concentrations when available. Instead, the clinician must evaluate the intoxicated patient based on clinical presentation and routine laboratory measurements.
In the future, further derivatives of these classes may appear in recreational use and perhaps new classes will emerge. The line between legality and illegality is so fine for some substances that the determination will need to be made in court. Potential therapeutic uses of these agents will be difficult to explore because of their automatic designation as controlled substances. The practising clinician must approach ‘designer drug’-intoxicated patients symptomatically and continually be alert for new or unusual presentations of substance abusers.
Similar content being viewed by others
References
Allcott JV, Barnhart RA, Mooney LA. Acute lead poisoning in two users of illicit methamphetamine. Journal of the American Medical Association 258: 510–511, 1987
Angelos SA, Meyers JA. The isolation and identification of precursors and reaction products in the clandestine manufacture of methaqualone and mecloqualone. Journal of Forensic Science 30: 1022–1047, 1985
Ayers PR. Amphetamine cardiomyopathy (letter). Annals of Internal Medicine 98: 110, 1983
Ayres WA, Starsiak MJ, Sokolay P. The bogus drug: three methyl and alpha methyl fentanyl sold as ‘china white’. Journal of Psychedelic Drugs 13: 91–93, 1981
Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), seven cases. Neurology 35: 949–956, 1985
Bohn G. Illegally manufactured 2,5-dimethoxy-4-bromoamphetamine in connection with a fatal intoxication. Toxichemistry 14: 140–141, 1981
Bowen JS, Davis GB, Kearney TE, Bardin J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. Journal of the American Medical Association 249: 1477–1479, 1983
Brittain JL. China white: the bogus drug. Journal of Toxicology and Clinical Toxicology 19: 1123–1126, 1982
Brown CR, Osterloh J. Journal of the American Medical Association. In press, 1987
Budd RD. Methaqualone RIA structure versus reactivity. Clinical Toxicology 16: 209–217, 1980b
Budd RD. Phencyclidine (PCP): structure versus reactivity. Clinical Toxicology 18: 1033–1041, 1981
Budd RD. PHP, a new drug of abuse. New England Journal of Medicine 303: 588, 1980a
Buhrich N, Morris G, Cook G. Bromo-DMA: the Australasian hallucinogen? Australia and New Zealand Journal of Psychiatry 17: 275–279, 1983
Burns RS, LeWitt PA, Ebert MH, Pakkenberg J, Kopin IJ. The clinical syndrome of striatal dopamine deficiency, parkinsonism induced by 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP). New England Journal of Medicine 312: 1418–1421, 1985
Call TD, Hartneck J, Dickinson WA, Harman CW, Bartel AG. Acute cardiomyopathy secondary to intravenous amphetamine abuse. Annals of Internal Medicine 97: 559–560, 1982
Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Archives of General Psychiatry 44: 286–294, 1987
Cimbura G. 3, 4-methylenedioxyamphetamine (MDA): analytical and forensic aspects of fatal poisoning. Journal of Forensic Science 17: 329–333, 1972
Cimbura G. PMA deaths in Ontario. Canadian Medical Association Journal 110: 1263–1267, 1974
Cooper D, Jacob M, Allen A. Identification of fentanyl derivatives. Journal of Forensic Science 31: 511–528, 1986
Daenens P, Van Boven M. The identification of quinazolinones on the illicit market. Journal of Forensic Science 21: 552–563, 1976
Davis WM, Borne RF. Pharmacologic investigation of compounds related to 3,4-methylenedioxyamphetamine (MDA). Substance Alcohol Actions Misuse 5: 105–110, 1984
Delaney P, Estes M. Intracranial hemorrhage with amphetamine use. Neurology 30: 1125–1128, 1980
Dowling GP, McDonough ET, Bost RO. ‘Eve’ and ‘Ecstasy’, a report of fíve deaths associated with the use of MDEA and MDMA. Journal of the American Medical Association 257: 1615–1617, 1987
Downing J. The psychological and physiological effects of MDMA on normal volunteers. Journal of Psychoactive Drugs 18: 335–340, 1986
Fruncillo RJ. Toxin-induced parkinsonism: recent developments. American Family Physician 33: 251–254, 1986
Gaston TR, Rasmussen GT. Identification of 3,4 methylenedioxymethamphetamine. Microgram 5: 60–63, 1972
Giannini AJ, Castellani S. A case of phenylcyclohexylpyrrolidine (PHP) intoxication treated with physostigmine. Journal of Toxicology and Clinical Toxicology 19: 505–508, 1982
Ginsberg MD, Hertzman M, Schmidt-Nowara WW. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure, a syndrome resembling heatstroke. Annals of Internal Medicine 73: 81–85, 1970
Greer G, Tolber R. Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs 18: 319, 1986
Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process? American Journal of Psychotherapy 40: 393–404, 1986
Hayner GN, McKinney H. MDMA: the dark side of ecstasy. Journal of Psychoactive Drugs 18: 341–347, 1986
Kalant H, Kalant OJ. Death in amphetamine users: causes and rates. Journal of the Canadian Medical Association 112: 299–304, 1975
Kamenka JM, Chiche B, Goudal R, Geneste P, Vignon J, et al. Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl)piperadine derivatives. Journal of Medicinal Chemistry 25: 431–435, 1982
Kendrick WC, Hull AR, Knochel JP. Rhabdomyolysis and shock after intravenous amphetamine administration. Annals of Internal Medicine 86: 381–387, 1977
Kojima T, Une I, Yashiki M, Noda J, Sakai K, et al. Fatal methamphetamine poisoning associated with hyperpyrexia. Forensic Science International 24: 87–93, 1984
Kram TC, Cooper DA, Allen AC. Behind the identification of china white. Analytical Chemistry 53: 1379A-1386A, 1981
Langston JW. MPTP and Parkinson’s disease. Trends in Neuroscience 8: 79–83, 1985
Langston JW, Ballard P. Parkinsonism induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of parkinson’s disease. Canadian Journal of Neurological Sciences 1: 160–165, 1984
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980, 1983
Langston JW, Irwin I, Langston EB, Forno LS. l-methyl-4-phen-ylpyridinium ion (MPP+ ): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neuroscience Letters 48: 87–92, 1984
Lukaszewski T. 3,4-methylenedioxyamphetamine overdose. Clinical Toxicology 15: 405–409, 1979
McCall RB. Effects of hallucinogenic drugs on serotonergic neuronal systems. Pharmacology Biochemistry Behavior 24: 359–363, 1986
Nakamura GR, Griesemer EC, Joiner LE, Noguchi TT. Determination of 1-(1-phenylcyclohexylpyrrolidine (PHP) in postmortem specimens: a case report. Clinical Toxicology 14: 383–388, 1979
Neill JR. More than medical significance: LSD and American psychiatry 1953 to 1966. Journal of Psychoactive Drugs 19: 39–40, 1987
Nichols DE. Structure-activity relationships of phenethylamine hallucinogens. Journal of Pharmaceutical Sciences 70: 839–849, 1981
Noggle FT, Clark CR, Davenport TW, Coker ST. Synthesis, identification and acute toxicity of alpha-benzylphenethylamine and alpha-benzyl-N-methylphenethylamine: contaminants in clandestine preparation of amphetamine and methamphetamine. Journal of the Association of Official Analytical Chemists 68: 1213–1222, 1985
Olson KR, Benowitz NL. Environmental and drug-induced hyperthermia: pathophysiology, recognition, and management. Emergency Medical Clinics of North America 2: 459–474, 1984
Ragan FA, Hite SA, Samuels MS, Garey RE. 4-Bromo-2,5-dimethoxyphenethylamine: identification of a new street drug. Journal of Analytical Toxicology 9: 91–93, 1985
Reed D, Cravey RH, Sedgwick PR. A fatal case involving methylenedioxyamphetamine. Clinical Toxicology 5: 3–6, 1972
Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986–988, 1985
Schmidt CJ, Wu L, Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analog. European Journal of Pharmacology 124: 175–178, 1986
Shannon HE, McQuinn RL, Vaupel B, Cone EJ. Effects of cycloalkyl ring analogs of phencyclidine on behavior in rodents. Journal of Pharmacology and Experimental Therapeutics 224: 327–333, 1983
Shulgin AT. Chemistry of phenethylamines related to mescaline. Journal of Pychoactive Drugs 11: 41–52, 1979
Shulgin AT. Profiles of psychedelic drugs: DOB. Journal of Psychoactive Drugs 13: 99, 1981
Shulgin AT. Profiles of psychedelic drugs: STP. Journal of Psychedelic Drugs 9: 171–172, 1977
Shulgin AT. Profiles of psychedelic drugs: TMA-2. Journal of Psychedelic Drugs 8: 169, 1976
Shulgin AT. The background and chemistry of MDMA. Journal of Psychoactive Drugs 18: 291–304, 1986
Shulgin AT, Jacob P. Potential misrepresentation of 3, 4-methylenedioxyamphetamine (MDA): a toxicologic warning. Journal of Analytical Toxicology 6: 71–75, 1982
Shulgin AT, MacLean DE. Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clinical Toxicology 9: 553–560, 1976
Shulgin AT, Sargent T, Naranjo C. Animal pharmacology and human pharmacology of 3-methoxy-4,5-methylenedioxyisopropylamine (MMDA). Pharmacology 10: 12–18, 1973
Siegel RK. MDMA, nonmedical use and intoxication. Journal of Psychoactive Drugs 18: 349–354, 1986
Simpson DL, Rumack BH. Methylenedioxyamphetamine: clinical description of overdose, death and review of pharmacology. Archives of Internal Medicine 141: 1507–1509, 1981
Snyder SH, Faillace L, Hollister L. 2,5-Dimethoxy-4-methylamphetamine (STP): a new hallucinogenic drug. Science 158: 669–670, 1967
Soine WH, Balster RL, Berglund KE, Martin CD, Agee DT. Identification of a new phencyclidine analog, l-(l-phenylcyclohexyl)-4-methylpiperidine, as a drug of abuse. Journal of Analytical Toxicology 6: 41–43, 1982
Soine WH, Vincek WC, Agee DT. Phencyclidine contaminant generates cyanide. New England Journal of Medicine 301: 438, 1979
Soliman FSG, Shafik RM, Elnenaey EA. Synthesis of methaqualone and its diphasic titration in pure and tablet forms. Journal of Pharmaceutical Sciences 67: 411–413, 1978
Stern Y, Langston JW. Intellectual changes in patients with MPTPinduced parkinsonism. Neurology 35: 1506–1509, 1985
Winek CL, Collom WD, Bricker JD. A death due to 4-bromo-2, 5-dimethoxyamphetamine. Clinical Toxicology 18: 267–271, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buchanan, J.F., Brown, C.R. ‘Designer Drugs’. Dis-Manage-Health-Outcomes 3, 1–17 (1988). https://doi.org/10.1007/BF03259928
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259928